258 related articles for article (PubMed ID: 30204261)
1. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
2. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
Yahouédéhou SCMA; da Guarda CC; Figueiredo CVB; Santiago RP; Carvalho SP; Fiuza LM; Ndidi US; Oliveira RM; Carvalho MOS; Nascimento VML; Rocha LC; Lyra IM; Adorno EV; Goncalves MS
PLoS One; 2019; 14(7):e0218040. PubMed ID: 31306416
[TBL] [Abstract][Full Text] [Related]
4. An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
Figueiredo L; Morrone K; Wei C; Ireland K; Cohen HW; Driscoll C; Manwani D
Blood Cells Mol Dis; 2017 Jul; 66():19-23. PubMed ID: 28783617
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
7. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
8. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
9. Measurements of red cell deformability and hydration reflect HbF and HbA
Parrow NL; Tu H; Nichols J; Violet PC; Pittman CA; Fitzhugh C; Fleming RE; Mohandas N; Tisdale JF; Levine M
Blood Cells Mol Dis; 2017 Jun; 65():41-50. PubMed ID: 28472705
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of oxygen gradient ektacytometry parameters between sickle cell patients with or without α-thalassaemia.
Boisson C; Renoux C; Nader E; Gauthier A; Poutrel S; Rab M; Fort R; Bertrand Y; Stauffer E; Cannas G; Kebaili K; Virot E; Hot A; Sheehan V; van Beers E; van Wijk R; Joly P; Connes P
Br J Haematol; 2021 Nov; 195(4):629-633. PubMed ID: 34396507
[TBL] [Abstract][Full Text] [Related]
11. Alpha thalassemia protects sickle cell anemia patients from macro-albuminuria through its effects on red blood cell rheological properties.
Lamarre Y; Romana M; Lemonne N; Hardy-Dessources MD; Tarer V; Mougenel D; Waltz X; Tressières B; Lalanne-Mistrih ML; Etienne-Julan M; Connes P
Clin Hemorheol Microcirc; 2014; 57(1):63-72. PubMed ID: 24004554
[TBL] [Abstract][Full Text] [Related]
12. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
Hebert N; Rakotoson MG; Bodivit G; Audureau E; Bencheikh L; Kiger L; Oubaya N; Pakdaman S; Sakka M; Di Liberto G; Chadebech P; Vingert B; Pirenne F; Galactéros F; Cambot M; Bartolucci P
Am J Hematol; 2020 Nov; 95(11):1235-1245. PubMed ID: 32681733
[TBL] [Abstract][Full Text] [Related]
13. Combined and differential effects of alpha-thalassemia and HbF-quantitative trait loci in Senegalese hydroxyurea-free children with sickle cell anemia.
Gueye Tall F; Martin C; Ndour EHM; Renoux C; Ly ID; Connes P; Gueye PM; Diallo RN; Diagne I; Diop PA; Cissé A; Lopez Sall P; Joly P
Pediatr Blood Cancer; 2019 Oct; 66(10):e27934. PubMed ID: 31322815
[TBL] [Abstract][Full Text] [Related]
14. The co-inheritance of alpha-thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival.
Rumaney MB; Ngo Bitoungui VJ; Vorster AA; Ramesar R; Kengne AP; Ngogang J; Wonkam A
PLoS One; 2014; 9(6):e100516. PubMed ID: 24978191
[TBL] [Abstract][Full Text] [Related]
15. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
16. Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients.
Kargutkar N; Nadkarni A
Expert Rev Hematol; 2023; 16(9):685-692. PubMed ID: 37394969
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
18. Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.
Bernaudin F; Arnaud C; Kamdem A; Hau I; Lelong F; Epaud R; Pondarré C; Pissard S
Blood Adv; 2018 Mar; 2(6):626-637. PubMed ID: 29555644
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
20. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
